NASDAQ •
Healthcare •
Biotechnology •
Quote as of 06/05/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization6.29 mln
Float1.25 mln
Earnings Date08/06/2026
EPS
1,488
Exceptional
P / E
0.00
Anomalous
Piotroski F-Score
2
/ 9
Weak
Relative Strength
21
/ 100
Significantly lagging
Debt / Equity
0.38
Low leverage
ROE
-255
Deeply negative
Business Description
Aptevo Therapeutics is a Seattle-based biotechnology company working to develop new cancer treatments by harnessing the body's own immune system. Founded in 2016, the company uses its proprietary antibody design technologies to create experimental drugs targeting blood cancers and solid tumors such as lung, breast, pancreatic, and prostate cancer. Several of its treatments are currently being tested in clinical trials, while others remain in earlier stages of research. Aptevo also works alongside Swedish biotech firm Alligator Bioscience to advance one of its key drug candidates.
